The results of our studies suggest that, in CD19 CAR T-cell therapy, targeted characteristics in r/r DLBCL could be used to evaluate the prognosis of T cell dysfunction related primary resistance. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.